OSAKA, Japan & CAMBRIDGE, Mass. - Friday, 09. February 2024 AETOSWire 

− Primary and Key Secondary Endpoints Were Met in Narcolepsy Type 1 Phase 2b Trial

− TAK-861 Was Found to be Generally Safe and Well-Tolerated

− Results Will be Presented at an Upcoming Scientific Congress

(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced positive topline results from a randomized, double-blind, placebo-controlled, multiple dose Phase 2b trial evaluating TAK-861, an oral orexin receptor 2 (OX2R) agonist, in patients with narcolepsy type 1.

Narcolepsy is a chronic, rare neurological disorder of central hypersomnolence with significant unmet need despite multiple approved therapies. It is currently classified into two different types: narcolepsy type 1 (NT1) caused by significant loss of orexin neurons with resulting lack of orexin, and narcolepsy type 2 (NT2) where orexin levels are generally normal. Stimul ... Read more »

LAS VEGAS - Friday, 09. February 2024

(BUSINESS WIRE)--Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, products and services, the leading third-party support provider for Oracle and SAP software, and a Salesforce and AWS partner, today announced it will report earnings after market close on February 28, 2024. The company will host a conference call and webcast on that date to discuss the fourth quarter and fiscal year 2023 results and offer commentary on 2024 at 5:00 p.m. Eastern / 2:00 p.m. Pacific time.

A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184.

A replay of the webcast will be available for one year following the event.

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI), a Russell 2000® ... Read more »